Immunotherapy after high-dose chemotherapy leads to favorable outcomes in acute myeloid leukemia
Compulsory jabs: Pressure mounts on anti-vaxxers
10 September 2021IASLC molecular subcommittee lung cancer dataset develops international biomarker snapshot
10 September 2021Immunotherapy after high-dose chemotherapy leads to favorable outcomes in acute myeloid leukemia
A clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and Johns Hopkins Sidney Kimmel Comprehensive Cancer Center found that high-dose cytarabine followed by subsequent immunotherapy treatment with pembrolizumab benefited patients with resistant or relapsed acute myeloid leukemia (AML), a highly aggressive cancer.
